Top

Published in:

01-08-2016 | Clinical trial

Characteristics and prognosis of interval cancers after biennial screen-film or full-field digital screening mammography

Authors: Roy J. P. Weber, Rob M. G. van Bommel, Marieke W. Louwman, Joost Nederend, Adri C. Voogd, Frits H. Jansen, Vivianne C. G. Tjan-Heijnen, Lucien E. M. Duijm

Published in: Breast Cancer Research and Treatment | Issue 3/2016

Abstract

We determined the characteristics and prognosis of interval breast cancers (IC) at screen-film (SFM) and full-field digital (FFDM) screening mammography. The study population consisted of 417,746 consecutive screening mammograms (302,699 SFM screens and 115,047 FFDM screens), obtained between 2000 and 2011. During 2-year follow-up, we collected breast imaging reports, surgical reports, and pathology results. A total of 800 ICs had been diagnosed in the screened population, of which 288 detected in the first year (early ICs) and 512 in the second year (late ICs) after a negative screen. 31.3 % of early IC’s and 19.1 % of late IC’s, respectively, were visible in retrospect on the latest previous screens, but had been missed during screening (P < 0.001). Missed invasive ICs were larger (28.5 mm vs. 23.9 mm, P = 0.003) and showed a higher fraction of T3+cancers (16.9 vs. 8.5 %, P = 0.02) than true ICs (i.e., not visible at the latest screen). A higher portion of missed than true ICs underwent mastectomy (44.7 vs. 30.8 %, P = 0.002). We found no differences in mammographic and tumor characteristics for early ICs, detected either after SFM or FFDM. Late ICs following FFDM were more often true ICs than missed ICs (69.0 vs. 57.6 %, P = 0.03) and more often receptor triple negative (P = 0.02), compared to late ICs at SFM. Interval cancer subgroups showed comparable overall survival. Interval cancer subgroups show distinctive mammographic and tumor characteristics but a comparable overall survival.

Dowling EC, Klabunde C, Patnick J, Ballard-Barbash R (2010) Breast and cervical cancer screening programme implementation in 16 countries. J Med Screen 17(3):139–146. doi:10.1258/jms.2010.010033 CrossRefPubMed

Tornberg S, Kemetli L, Ascunce N, Hofvind S, Anttila A, Seradour B, Paci E, Guldenfels C, Azavedo E, Frigerio A, Rodrigues V, Ponti A (2010) A pooled analysis of interval cancer rates in six European countries. Eur J Cancer Prev 19(2):87–93. doi:10.1097/CEJ.0b013e32833548ed CrossRefPubMed

Nederend J, Duijm LE, Voogd AC, Groenewoud JH, Jansen FH, Louwman MW (2012) Trends in incidence and detection of advanced breast cancer at biennial screening mammography in The Netherlands: a population based study. Breast Cancer Res 14(1):R10. doi:10.1186/bcr3091 CrossRefPubMedPubMedCentral

Perry N, Broeders M, de Wolf C, Tornberg S, Holland R, van Korsa L (2008) European guidelines for quality assurance in breast cancer screening and diagnosis. Fourth edition–summary document. Ann Oncol 19(4):614–622. doi:10.1093/annonc/mdm481 CrossRefPubMed

Burrell HC, Sibbering DM, Wilson AR, Pinder SE, Evans AJ, Yeoman LJ, Elston CW, Ellis IO, Blamey RW, Robertson JF (1996) Screening interval breast cancers: mammographic features and prognosis factors. Radiology 199(3):811–817CrossRefPubMed

Klemi PJ, Toikkanen S, Rasanen O, Parvinen I, Joensuu H (1997) Mammography screening interval and the frequency of interval cancers in a population-based screening. Br J Cancer 75(5):762–766CrossRefPubMedPubMedCentral

Porter PL, El-Bastawissi AY, Mandelson MT, Lin MG, Khalid N, Watney EA, Cousens L, White D, Taplin S, White E (1999) Breast tumor characteristics as predictors of mammographic detection: comparison of interval- and screen-detected cancers. J Natl Cancer Inst 91(23):2020–2028. doi:10.1093/Jnci/91.23.2020 CrossRefPubMed

Schroen AA, Wobbes T, van der Sluis RF (1996) Interval carcinomas of the breast: a group with intermediate outcome. J Surg Oncol 63(3):141–144. doi:10.1002/(sici)1096-9098(199611)63:3<141:aid-jso2>3.0.co;2-d CrossRefPubMed

Vitak B, Olsen KE, Manson JC, Arnesson LG, Stal O (1999) Tumour characteristics and survival in patients with invasive interval breast cancer classified according to mammographic findings at the latest screening: a comparison of true interval and missed interval cancers. Eur Radiol 9(3):460–469CrossRefPubMed

10.

Musolino A, Michiara M, Conti GM, Boggiani D, Zatelli M, Palleschi D, Bella MA, Sgargi P, Di Blasio B, Ardizzoni A (2012) Human epidermal growth factor receptor 2 status and interval breast cancer in a population-based cancer registry study. J Clin Oncol 30(19):2362–2368. doi:10.1200/jco.2011.37.6434 CrossRefPubMed

11.

Rayson D, Payne JI, Abdolell M, Barnes PJ, MacIntosh RF, Foley T, Younis T, Burns A, Caines J (2011) Comparison of clinical-pathologic characteristics and outcomes of true interval and screen-detected invasive breast cancer among participants of a Canadian breast screening program: a nested case-control study. Clin Breast Cancer 11(1):27–32. doi:10.3816/CBC.2011.n.005 CrossRefPubMed

12.

Porter GJ, Evans AJ, Burrell HC, Lee AH, Ellis IO, Chakrabarti J (2006) Interval breast cancers: prognostic features and survival by subtype and time since screening. J Med Screen 13(3):115–122. doi:10.1258/096914106778440572 CrossRefPubMed

13.

Hofvind S, Geller B, Skaane P (2008) Mammographic features and histopathological findings of interval breast cancers. Acta Radiol 49(9):975–981. doi:10.1080/02841850802403730 CrossRefPubMedPubMedCentral

14.

Domingo L, Salas D, Zubizarreta R, Bare M, Sarriugarte G, Barata T, Ibanez J, Blanch J, Puig-Vives M, Fernandez A, Castells X, Sala M (2014) Tumor phenotype and breast density in distinct categories of interval cancer: results of population-based mammography screening in Spain. Breast Cancer Res 16(1):R3. doi:10.1186/bcr3595 CrossRefPubMedPubMedCentral

15.

Hoff SR, Abrahamsen AL, Samset JH, Vigeland E, Klepp O, Hofvind S (2012) Breast cancer: missed interval and screening-detected cancer at full-field digital mammography and screen-film mammography– results from a retrospective review. Radiology 264(2):378–386. doi:10.1148/radiol.12112074 CrossRefPubMed

16.

Nederend J, Duijm LE, Louwman MW, Coebergh JW, Roumen RM, Lohle PN, Roukema JA, Rutten MJ, van Steenbergen LN, Ernst MF, Jansen FH, Plaisier ML, Hooijen MJ, Voogd AC (2014) Impact of the transition from screen-film to digital screening mammography on interval cancer characteristics and treatment - a population based study from the Netherlands. Eur J Cancer 50(1):31–39. doi:10.1016/j.ejca.2013.09.018 CrossRefPubMed

17.

Duijm LE, Groenewoud JH, Hendriks JH, de Koning HJ (2004) Independent double reading of screening mammograms in The Netherlands: effect of arbitration following reader disagreements. Radiology 231(2):564–570. doi:10.1148/radiol.2312030665 CrossRefPubMed

18.

Fracheboud J, de Koning HJ, Boer R, Groenewoud JH, Verbeek AL, Broeders MJ, van Ineveld BM, Hendriks JH, de Bruyn AE, Holland R, van der Maas PJ (2001) Nationwide breast cancer screening programme fully implemented in The Netherlands. Breast 10(1):6–11. doi:10.1054/brst.2000.0212 CrossRefPubMed

19.

American College of Radiology (2003) Breast imaging reporting and data system (BI-RADS), 2nd edn. American College of Radiology, Reston

20.

Klompenhouwer EG, Voogd AC, den Heeten GJ, Strobbe LJ, de Haan AF, Wauters CA, Broeders MJ, Duijm LE (2015) Blinded double reading yields a higher programme sensitivity than non-blinded double reading at digital screening mammography: a prospected population based study in the south of The Netherlands. Eur J Cancer 51(3):391–399. doi:10.1016/j.ejca.2014.12.008 CrossRefPubMed

21.

Duijm LE, Groenewoud JH, Jansen FH, Fracheboud J, van Beek M, de Koning HJ (2004) Mammography screening in the Netherlands: delay in the diagnosis of breast cancer after breast cancer screening. Br J Cancer 91(10):1795–1799. doi:10.1038/sj.bjc.6602158 CrossRefPubMedPubMedCentral

22.

Maes RM, Dronkers DJ, Hendriks JH, Thijssen MA, Nab HW (1997) Do non-specific minimal signs in a biennial mammographic breast cancer screening programme need further diagnostic assessment? Br J Radiol 70:34–38CrossRefPubMed

23.

van Luijt PA, Fracheboud J, Heijnsdijk EA, den Heeten GJ, de Koning HJ, National Evaluation Team for Breast Cancer Screening in Netherlands Study G (2013) Nation-wide data on screening performance during the transition to digital mammography: observations in 6 million screens. Eur J Cancer 49(16):3517–3525. doi:10.1016/j.ejca.2013.06.020 CrossRef

24.

Bluekens AM, Holland R, Karssemeijer N, Broeders MJ, den Heeten GJ (2012) Comparison of digital screening mammography and screen-film mammography in the early detection of clinically relevant cancers: a multicenter study. Radiology 265(3):707–714. doi:10.1148/radiol.12111461 CrossRefPubMed

25.

Karssemeijer N, Bluekens AM, Beijerinck D, Deurenberg JJ, Beekman M, Visser R, van Engen R, Bartels-Kortland A, Broeders MJ (2009) Breast cancer screening results 5 years after introduction of digital mammography in a population-based screening program. Radiology 253(2):353–358. doi:10.1148/radiol.2532090225 CrossRefPubMed

26.

Feeley L, Kiernan D, Mooney T, Flanagan F, Hargaden G, Kell M, Stokes M, Kennedy M (2011) Digital mammography in a screening programme and its implications for pathology: a comparative study. J Clin Pathol 64(3):215–219. doi:10.1136/jcp.2010.085860 CrossRefPubMed

27.

Weber RJ, Nederend J, Voogd AC, Strobbe LJ, Duijm LE (2015) Screening outcome and surgical treatment during and after the transition from screen-film to digital screening mammography in the south of The Netherlands. Int J Cancer 137(1):135–143. doi:10.1002/ijc.29354 CrossRefPubMed

28.

Bluekens AM, Karssemeijer N, Beijerinck D, Deurenberg JJ, van Engen RE, Broeders MJ, den Heeten GJ (2010) Consequences of digital mammography in population-based breast cancer screening: initial changes and long-term impact on referral rates. Eur Radiol 20(9):2067–2073. doi:10.1007/s00330-010-1786-7 CrossRefPubMedPubMedCentral

29.

Pisano ED, Gatsonis C, Hendrick E, Yaffe M, Baum JK, Acharyya S, Conant EF, Fajardo LL, Bassett L, D’Orsi C, Jong R, Rebner M, Digital Mammographic Imaging Screening Trial Investigators G (2005) Diagnostic performance of digital versus film mammography for breast-cancer screening. N Engl J Med 353(17):1773–1783. doi:10.1056/NEJMoa052911 CrossRefPubMed

30.

Lewin JM, Hendrick RE, D’Orsi CJ, Isaacs PK, Moss LJ, Karellas A, Sisney GA, Kuni CC, Cutter GR (2001) Comparison of full-field digital mammography with screen-film mammography for cancer detection: results of 4,945 paired examinations. Radiology 218(3):873–880CrossRefPubMed

31.

Juel IM, Skaane P, Hoff SR, Johannessen G, Hofvind S (2010) Screen-film mammography versus full-field digital mammography in a population-based screening program: the Sogn and Fjordane study. Acta Radiol 51(9):962–968. doi:10.3109/02841851.2010.504969 CrossRefPubMed

32.

Domingo L, Romero A, Belvis F, Sanchez M, Ferrer J, Salas D, Ibanez J, Vega A, Ferrer F, Laso MS, Macia F, Castells X, Sala M (2011) Differences in radiological patterns, tumour characteristics and diagnostic precision between digital mammography and screen-film mammography in four breast cancer screening programmes in Spain. Eur Radiol 21(9):2020–2028. doi:10.1007/s00330-011-2143-1 CrossRefPubMed

33.

Otten JD, Karssemeijer N, Hendriks JH, Groenewoud JH, Fracheboud J, Verbeek AL, de Koning HJ, Holland R (2005) Effect of recall rate on earlier screen detection of breast cancers based on the Dutch performance indicators. J Natl Cancer Inst 97(10):748–754. doi:10.1093/jnci/dji131 CrossRefPubMed

34.

Pisano ED, Gatsonis C, Hendrick E, Yaffe M, Baum JK, Acharyya S, Conant EF, Fajardo LL, Bassett L, D’Orsi C, Jong R, Rebner M (2005) Diagnostic performance of digital versus film mammography for breast-cancer screening. N Engl J Med 353(17):1773–1783. doi:10.1056/NEJMoa052911 CrossRefPubMed

35.

Skaane P, Skjennald A (2004) Screen-film mammography versus full-field digital mammography with soft-copy reading: randomized trial in a population-based screening program–the Oslo II Study. Radiology 232(1):197–204. doi:10.1148/radiol.2321031624 CrossRefPubMed

36.

Hofvind S, Skaane P, Elmore JG, Sebuodegard S, Hoff SR, Lee CI (2014) Mammographic performance in a population-based screening program: before, during, and after the transition from screen-film to full-field digital mammography. radiology 272:252–262. doi:10.1148/radiol.14131502 CrossRef

37.

White E, Miglioretti DL, Yankaskas BC, Geller BM, Rosenberg RD, Kerlikowske K, Saba L, Vacek PM, Carney PA, Buist DS, Oestreicher N, Barlow W, Ballard-Barbash R, Taplin SH (2004) Biennial versus annual mammography and the risk of late-stage breast cancer. J Natl Cancer Inst 96(24):1832–1839. doi:10.1093/jnci/djh337 CrossRefPubMed

38.

Collett K, Stefansson IM, Eide J, Braaten A, Wang H, Eide GE, Thoresen SO, Foulkes WD, Akslen LA (2005) A basal epithelial phenotype is more frequent in interval breast cancers compared with screen detected tumors. Cancer Epidemiol Biomarkers Prev 14(5):1108–1112. doi:10.1158/1055-9965.epi-04-0394 CrossRefPubMed

39.

Boyd NF, Guo H, Martin LJ, Sun L, Stone J, Fishell E, Jong RA, Hislop G, Chiarelli A, Minkin S, Yaffe MJ (2007) Mammographic density and the risk and detection of breast cancer. N Engl J Med 356(3):227–236. doi:10.1056/NEJMoa062790 CrossRefPubMed

40.

Mandelson MT, Oestreicher N, Porter PL, White D, Finder CA, Taplin SH, White E (2000) Breast density as a predictor of mammographic detection: comparison of interval- and screen-detected cancers. J Natl Cancer Inst 92(13):1081–1087CrossRefPubMed

41.

Emaus MJ, Bakker MF, Peeters PH, Loo CE, Mann RM, de Jong MD, Bisschops RH, Veltman J, Duvivier KM, Lobbes MB, Pijnappel RM, Karssemeijer N, de Koning HJ, van den Bosch MA, Monninkhof EM, Mali WP, Veldhuis WB, van Gils CH (2015) MR Imaging as an additional screening modality for the detection of breast cancer in women aged 50–75 years with extremely dense breasts: the dense trial study Design. Radiology 277(2):527–537. doi:10.1148/radiol.2015141827 CrossRefPubMed

42.

Raja MA, Hubbard A, Salman AR (2001) Interval breast cancer: is it a different type of breast cancer? Breast 10(2):100–108. doi:10.1054/brst.2000.0217 CrossRefPubMed

43.

Mahmood U, Hanlon AL, Koshy M, Buras R, Chumsri S, Tkaczuk KH, Cheston SB, Regine WF, Feigenberg SJ (2013) Increasing national mastectomy rates for the treatment of early stage breast cancer. Ann Surg Oncol 20(5):1436–1443. doi:10.1245/s10434-012-2732-5 CrossRefPubMed

44.

Nederend J, Duijm LE, Louwman MW, Roumen RM, Jansen FH, Voogd AC (2014) Trends in surgery for screen-detected and interval breast cancers in a national screening programme. Br J Surg 101(8):949–958. doi:10.1002/bjs.9530 CrossRefPubMed

45.

Bulliard JL, Sasieni P, Klabunde C, De Landtsheer JP, Yankaskas BC, Fracheboud J (2006) Methodological issues in international comparison of interval breast cancers. Int J Cancer 119(5):1158–1163. doi:10.1002/ijc.21941 CrossRefPubMed

46.

Smith-Bindman R, Chu PW, Miglioretti DL, Sickles EA, Blanks R, Ballard-Barbash R, Bobo JK, Lee NC, Wallis MG, Patnick J, Kerlikowske K (2003) Comparison of screening mammography in the United States and the United kingdom. JAMA 290(16):2129–2137. doi:10.1001/jama.290.16.2129 CrossRefPubMed

Title: Characteristics and prognosis of interval cancers after biennial screen-film or full-field digital screening mammography
Authors: Roy J. P. Weber
Rob M. G. van Bommel
Marieke W. Louwman
Joost Nederend
Adri C. Voogd
Frits H. Jansen
Vivianne C. G. Tjan-Heijnen
Lucien E. M. Duijm
Publication date: 01-08-2016
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 3/2016
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-016-3882-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

ACC 2024 Congress

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2016

Ultrasound-guided breast-conserving surgery for early-stage palpable and nonpalpable invasive breast cancer: decreased excision volume at unchanged tumor-free resection margin

Endocrine treatment-associated cognitive impairment in breast cancer survivors: evidence from published studies

Polygenic risk score is associated with increased disease risk in 52 Finnish breast cancer families

Relationship of ZNF423 and CTSO with breast cancer risk in two randomised tamoxifen prevention trials

The impact of patient navigation on the delivery of diagnostic breast cancer care in the National Patient Navigation Research Program: a prospective meta-analysis

Predictors of enduring clinical distress in women with breast cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer